Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Inför Kebnis bokslutskommuniké 2023: Ställ din fråga till VD Torbjörn Saxmo

Kebni AB publicerar sin bokslutskommuniké 2023 på fredag den 16 februari 2024. En inspelad rapportpresentation och Q&A med Kebnis VD Torbjörn Saxmo kommer att publiceras samma dag i Kebnis digitala kanaler samt på Youtube-kanalen Penser Play .Mejla in din fråga:Det finns nu möjlighet att skicka in frågor till Q&A-segmentet. Mejla din fråga till maya.larsson@kebni.com senast 10.00 den 16:e februari. Skriv ”Q&A” i ämnesraden. Välkommen med din fråga!  Om KebniKebni har en lång historia och stor erfarenhet inom Inertial

DOF Group ASA - Contract Award and Contract Extension in APAC

DOF is pleased to announce a contract award and a contract extension securing further backlog for the APAC region. The latest contract secured for the region will utilise Skandi Hercules and see the vessel fully utilised off the Australian coast into Q3 2024. The contracted scope includes project management and engineering, logistics support and execution of various inspection, maintenance, and repair (IMR) activities.  In addition, a contract extension has been secured for Skandi Singapore with the vessel fully committed through Q3 2024 with further options available into Q1 2025.

Helping people is her biggest driver

Managing a region including 33 countries with a vast diversity in cultures, politics, economics and healthcare market dynamics might sound challenging. Zeynep Sanver, President Central and Eastern Europe at Getinge, addresses it with a strong belief in capable, empowered local teams and a passion for helping people. “Joining the healthcare sector was a conscious decision after I completed my master’s degree in engineering business management. I have always been thrilled to be part of an industry where the focus is on helping people overcome difficult situations,” says Zeynep

Notice of Axfood’s 2024 Annual General Meeting

Welcome to the Annual General Meeting (AGM) of Axfood AB (publ), corporate registration number 556542-0824, to be held on Wednesday, 20 March 2024 at 5:00 p.m. at Münchenbryggeriet, Torkel Knutssonsgatan 2 in Stockholm, Sweden. Registration for the AGM will open at 4:00 p.m. The Board of Directors has decided that shareholders may also exercise their voting rights at the AGM by postal voting, as stipulated in Axfood’s Articles of Association.Registration and notification Shareholders who wish to participate in the proceedings of the AGM must: · be registered as shareholders in the

STOREBRAND ASA: Recommendation of Board members for 2024-2025

Nomination committee's recommendation of Board members for the election period 2024-2025 to the Annual General Meeting The Board of Directors in Storebrand ASA consist of ten members, of which seven are shareholder elected and the other three are employee elected. In connection with the Annual General Meeting's election of the board for the election period 2024-2025, Didrik Munch, Karin Bing Orgland and Fredrik Åtting have chosen to retire from their board positions. The Nomination Committee of Storebrand ASA has unanimously decided to nominate the following as board members for the

Kemira Oyj: Shareholding of Solidium Oy in Kemira has decreased below 5.00 per cent

Kemira Oyj, Stock Exchange Release, February 13, 2024 at 09.50 am (EET)Kemira Oyj: Shareholding of Solidium Oy in Kemira has decreased below 5.00 per cent   This is a notification in accordance with Chapter 9, Section 10 of the Finnish Securities Market Act. Kemira Oyj has on February 13, 2024 received a notification of a change in shareholding in accordance with Chapter 9, Section 5 of the Securities Market Act.   According to the notification, the shareholding of Solidium Oy in Kemira Oyj decreased below 5.00% on February 13, 2024 and is 0 shares representing 0.00% of the

DNB Markets – Episurf Medical: Sales moving in the right direction

Q4 sales were in line with our forecast, but operating expenses were higher. Overall, we believe sales growth will be the most important parameter to track short- to medium-term. If growth continues to be strong in the OUS market and uptake of the patellofemoral system takes off in the US, we believe the company would enter a phase of high growth. It had cSEK58m cash at end-Q4, which should last until end-2024. We have tweaked our forecasts, but reiterate our fair value of SEK1.5–4.5.Q4 sales in line with our forecast but earnings lower. Sales were SEK3.2m (we forecast SEK3.3m) but

Crunchfish Digital Cash protector increases the security for 3rd party offline payment services

Protecting offline payment applications is hard as offline payment introduces specific risks relating to bearer instruments and double-spending. Crunchfish Digital Cash offline solution enables offline payment for 3rd party online payment services by offering a secure, isolated runtime and encrypted storage with rollback protection for all offline assets. Crunchfish announces now the Digital Cash protector as an offline payment application protection add-on for 3rd party offline payment services.   Offline payments introduce specific risks that need careful consideration. Since

Tokmanni Group’s Capital Markets Day 2024: Tokmanni continues its strong growth and updates its financial targets

Tokmanni Group Corporation        Stock exchange release        13 February 2024 at 9:30 amTokmanni expanded its operations beyond Finland in line with its strategy by buying the Swedish discount store chain Dollarstore in August 2023. Together, Tokmanni and Dollarstore form one of the leading discount retailers in the Nordic markets. Tokmanni and Dollarstore are determined to continue taking measures to promote strong growth. Tokmanni Group's long-term vision is to become the leading discount retailer in Northern Europe. Tokmanni Group’s target is to have a store network of over 360

Valmet to deliver electrostatic precipitators to Nordic Paper’s Bäckhammar mill in Sweden

Valmet Oyj’s press release February 13, 2024 at 9:30 a.m. EETValmet will deliver electrostatic precipitators (ESP) for the existing recovery boiler in Nordic Paper’s Bäckhammar mill in Kristinehamn, Sweden. The take over is scheduled to be in the end of 2025. The order is part of Nordic Paper’s investments to further improve the sustainability performance and the competitiveness of the company’s Bäckhammar mill, which manufactures unbleached kraft papers of different qualities, primarily for packaging purposes. Through the installation of new electrostatic precipitators, the emissions of

Stora Enso publishes its Annual Report 2023

STORA ENSO OYJ ANNUAL FINANCIAL REPORT 13 February 2024 at 9:30 EETStora Enso’s Annual Report 2023 is published today at storaenso.com/annualreport .  The report includes a strategy review, sustainability reporting, corporate governance, remuneration report and financial report.   Stora Enso publishes its annual financial statements in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format of the report is Extensible Hypertext Markup Language (xHTML). In line with the ESEF requirements, the

Cline Scientific advisor discusses the future of cartilage damage treatment

A video interview featuring Professor Mats Brittberg, senior physician in orthopedics at Varberg Hospital and Professor at the University of Gothenburg talks about future treatments for cartilage damage has been published.Mats Brittberg, senior physician in orthopedics at Varberg Hospital and professor at the University of Gothenburg, is a scientific advisor to Cline Scientific. In the video published by BioStock, Brittberg discusses future treatments for cartilage damage and osteoarthritis. Brittberg highlights Cline's StemCART project and the work we are doing to develop an allogeneic

Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme

The milestone compensation is related to achieved development targets for the Xork enzyme that Genovis has out-licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases.Xork is derived from a streptococcal bacterial strain that does not infect humans. The pre-clinical data generated to date highlights Xork’s differentiated profile demonstrating very low cross-reactivity with naturally occurring antibodies in human sera while retaining efficient and specific cleavage of human IgG antibodies.

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"). The proceeds are intended to be used to strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen Curasight’

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Fourth quarter (October-December 2023) · Operating profit/loss amounted to SEK -5,212,694 (-3,951,799). · Loss for the period amounted to SEK -4,749,222 (-3,898,340). · Cash flow from operating activities totaled SEK 3,503,148 (5,516,307). · Earnings per share before dilution totaled SEK -0.24 (-0.20). Earnings per share after dilution totaled SEK -0.24 (-0.20). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year).   Period (January-December 2023) · Operating profit/loss amounted to SEK -17,096,277 (-19,362,750). · Loss for the period

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE[®]) and therapy (uTREAT[®]) · First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025. Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer

Amuse Presents Direct Integration with YouTube for Official Artist Channels

Managing music and artist content across YouTube can be challenging and tedious. To help DIY and independent artists gain control of their presence on the platform, global music company and distributor Amuse presents an automated integration with YouTube for Official Artist Channel (OAC) access. Eligible Amuse distribution users can now request their OAC with just a few clicks, merging all subscribers and content from different parts of YouTube into one convenient channel.The integration is the latest result of Amuse’s continued ambition to solve pain points for the DIY and independent

Camurus appoints Behshad Sheldon as President of Camurus Inc.

Lund, Sweden — 13 February 2024 — Camurus AB (NASDAQ STO: CAMX) today announced the appointment of Behshad Sheldon as President of Camurus Inc. and member of the company’s executive management team, starting 1 April 2024. Behshad has been a member of Camurus’ Board of Directors since 2018, contributing to Camurus’ development as a successful and profitable, commercial-stage pharmaceutical company. Behshad brings more than 25 years of experience from leading positions within the international pharmaceutical industry, including as President & CEO of Braeburn Pharmaceuticals up to 2017, and

Repurchases of shares by Attendo AB during week 6, 2024

On 9 February 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 43,382 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 8 February 2024. The repurchase program, which runs between 9 February 2024 and 24 April 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/

Esmaeilzadeh Holding publishes year-end report for 2023

“During the fourth quarter, we continued to consolidate and strengthen EHAB’s balance sheet, which resulted in new financing projects, structured processes, and in-depth operational work with our portfolio companies. The current economic conditions challenge the entire company group, and we are therefore positive that a majority of the portfolio continues to deliver stable financial results. EHAB’s highest priority is to position the company for long-term value creation, and we are convinced that our initiatives are taking us in the right direction.” - Saeid Esmaeilzadeh Financial

Navamedic ASA: Invitation to 2023 4th quarter presentation

Oslo, February 13, 2024 - Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning Eufemias gate 16 in Oslo and the event will start at 08.30 CET. A link to the webcast and the presentation will be available through the Navamedic web site on the following link: https://navamedic.com/investors/financial-results/ For further information, please contact: Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO, +47 917 62 842 E-mail: lars.hjarrand@

Repurchases of shares by Concentric AB during week 6, 2024

Between 5 February 2024 and 9 February 2024 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 19,025 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Metso awarded a major order for concentrator plant equipment for a copper project in Chile

Metso Corporation’s press release on February 13, 2024, at 09:00 a.m. EETMetso has been awarded a major order to deliver key concentrator equipment for a copper mining project in Chile. The value of the order is approximately EUR 55 million, and it is booked in the Minerals segment’s first-quarter 2024 orders received.The Metso delivery scope consists of high-capacity Nordberg® MP1250 secondary cone crushers, MF Series[TM] vibrating screens and energy-efficient Vertimill® VTM1500 regrinding mills. For the flotation and separation circuit, Metso will supply multiple TankCell® and

There are no items matching the current filter
There are no more items matching the current filter
Back to top